A large number of 5-HT receptors (>15) have been identified by molecular cloning technology over the past 10 years. This review briefly summarizes available information regarding the functional and therapeutic implications of serotonin receptor diversity for neurology and psychiatry. 5-HT receptors are divided into seven main families: 5-HT1, 5-HT2, 5-HT3, 5-HT4, 5-HT5, 5-HT6, and 5-HT7. Several families (e.g., 5-HT1 family) have many members (e.g., 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, 5-HT1F), each of which is encoded by a distinct gene product. In addition to the genomic diversity of 5-HT receptors, splice variants and editing isoforms exist for many of the 5-HT receptors, making the family even more diverse. Evidence that is summarized in this review suggests that 5-HT receptors represent novel therapeutic targets for a number of neurologic and psychiatric diseases including migraine headaches, chronic pain conditions, schizophrenia, anxiety, depression, eating disorders, obsessive compulsive disorder, pervasive developmental disorders, and obesity-related conditions (Type II diabetes, hypertension, obesity syndromes). It is possible that sub-type-selective serotonergic agents may revolutionize the treatment for a number of medical, psychiatric, and neurological disorders.
Rapport MM. The discovery of serotonin. Perspect Biol Med1997;40:260-273.
2.
Wooley DW, Shaw E.A biochemical and pharmacological sug-gestion about certain mental disorders. Proc Natl Acad Sci U S A1954;40:228-231.
3.
Roth BL, Meltzer H.The role of serotonin in schizophrenia. In: Bloom F, Kupfer D, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press; 1995. p. 1215-1227.
4.
Peroutka SJ, Snyder SH. Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol. Mol Pharmacol1979;16:687-699.
5.
Kroeze WK, Roth BL. The molecular biology of serotonin re-ceptors: therapeutic implications for the interface of mood and psychosis. Biol Psychiatry1998;44:1128-1142.
6.
Raymond JR, Albers FJ, Middleton JP. Functional expression of human 5-HT1A receptors and differential coupling to second messengers in CHO cells. Naunyn Schmiedebergs Arch Pharmacol1992;346:127-137.
7.
Fargin A, Raymond JR, Regan JW, Cotecchia S, Lefkowitz RJ, Caron MG. The genomic clone G-21 which resembles a beta-adrenergic receptor sequence encodes the 5-HT1A receptor. Nature1988;335:358-360.
8.
Chaput Y, de Montigny C, Blier P.Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: electrophysiological studies in the rat brain. Naunyn Schmiedebergs Arch Pharmacol1986;333:342-348.
9.
Chaput Y, de Montigny C, Blier P.Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments. An in vivo electrophysiologic study in the rat. Neuropsychopharmacology1991;5:219-229.
10.
Artigas F, Romero L, de Montigny C, Blier P.Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci1996;19:378-383.
11.
Berman RM, Anand A, Cappiello A, Miller HL, Hu XS, Oren DA, et al.The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial. Biol Psychiatry1999;45:1170-1177.
12.
Goldberg HL, Finnerty RJ. The comparative efficacy of buspirone and diazepam in the treatment of anxiety disorders. Am J Psychiatry1979;136:1184-1187.
13.
Wells BG, Chu CC, Johnson R, Nasdahl C, Ayubi MA, Sewell E, et al.Buspirone in the treatment of posttraumatic stress disorder. Pharmacotherapy1991;11:340-343.
14.
Rickles K, Amsterdam JD, Clary C, Puzzoli G, Schweizer E.Buspirone in the treatment of depression: a controlled study. J Clin Psychiatry1991;52:34-38.
15.
Blier P, Bergeron R.Sequential administration of augmentation strategies in treatment-resistant obsessive-compulsive disorder: preliminary findings. Int Clin Psychopharmacol1996;11:37-44.
16.
Hamblin MW, Metcalf MA, McGuffin RW, Karpells S.Molecular cloning and functional characterization of a human 5-HT1B serotonin receptor: a homologue of the rat 5-HT1B receptor with 5-HT1D-like pharmacological specificity. Biochem Biophys Res Commun1992;184:752-759.
17.
Weinshank RL, Zgombick JM, Macchi MJ, Branchek TA, Hartig PR. Human serotonin 1D receptor is encoded by a subfamily of two distinct genes: 5-HT1D alpha and 5-HT1D beta. Proc Natl Acad Sci U S A1992;89:3630-3634.
18.
Schoeffter P, Hoyer D.How selective is GR 43175? Interactions with functional 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol1989;340:135-138.
19.
Peroutka SJ, McCarthy BG. Sumatriptan (GR 43175) interacts selectively with 5-HT1B and 5-HT1D binding sites. Eur J Pharmacol1989;163:133-136.
20.
Doenicke A, Brand J, Perrin VL. Possible benefit of GR43175, a novel 5-HT1-like receptor agonist, for the acute treatment of severe migraine. Lancet1988;1:1309-1311.
21.
Pauwels PJ, John GW. Present and future of 5-HT receptor agonists as antimigraine drugs. Clin Neuropharmacol1999;22:123-136.
22.
Saudou F, Amara DA, Dierich A, LeMeur M, Ramboz S, Segu L, et al.Enhanced aggressive behavior in mice lacking 5-HT1B receptor. Science1994;265:1875-1878.
23.
Lucas JJ, Segu L, Hen R.5-Hydroxytryptamine1B receptors modulate the effect of cocaine on c-fos expression: converging evidence using 5-hydroxytryptamine1B knockout mice and the 5-hydroxytryptamine1B/1D antagonist GR127935. Mol Pharmacol1997;51:755-763.
24.
Lucas JJ, Yamamoto A, Scearce-Levie K, Saudou F, Hen R.Absence of fenfluramine-induced anorexia and reduced c-Fos induction in the hypothalamus and central amygdaloid complex of serotonin 1B receptor knock-out mice. J Neurosci1998;18:5537-5544.
25.
Scearce-Levie K, Viswanathan SS, Hen R.Locomotor response to MDMA is attenuated in knockout mice lacking the 5-HT1B receptor. Psychopharmacology (Berl)1999;141:154-161.
26.
Pineyro G, Castanon N, Hen R, Blier P.Regulation of [3H]5-HT release in raphe, frontal cortex and hippocampus of 5-HT1B knock-out mice. Neuroreport1995;7:353-359.
27.
Leonhardt S, Herrick-Davis K, Titeler M.Detection of a novel serotonin receptor subtype (5-HT1E) in human brain: interaction with a GTP-binding protein. J Neurochem1989;53:465-471.
28.
McAllister G, Charlesworth A, Snodin C, Beer MS, Noble AJ, Middlemiss DN, et al.Molecular cloning of a serotonin receptor from human brain (5HT1E): a fifth 5HT1-like subtype. Proc Natl Acad Sci U S A1992;89:5517-5521.
29.
Bouchelet I, Cohen Z, Case B, Seguela P, Hamel E.Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. Mol Pharmacol1996;50:219-223.
30.
Johnson KW, Schaus JM, Durkin MM, Audia JE, Kaldor SW, Flaugh ME, et al.5-HT1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs. Neuroreport1997;8:2237-2240.
31.
Johnson KW, Phebus LA, Cohen ML. Serotonin in migraine: theories, animal models and emerging therapies. Prog Drug Res1998;51:219-244.
32.
John GW, Pauwels PJ, Perez M, Halazy S, Le Grand B, Verscheure Y, et al.F 11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrin-sic activity at 5-HT1B/1D receptors in models relevant to mi-graine. J Pharmacol Exp Ther1999;290:83-95.
33.
Matz R, Rick W, Oh D, Thompson H, Gershon S.Clozapine-a potential antipsychotic agent without extrapyramidal manifestations. Curr Ther Res1974;16:687.
34.
Andree TH, Mikuni M, Tong CY, Koenig JI, Meltzer HY. Differential effect of subchronic treatment with various neuroleptic agents on serotonin 2 receptors in rat cerebral cortex. J Neurochem1986;46:191-197.
35.
Meltzer HY, Matsubara S, Lee J-C.Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther1989;251:238-246.
36.
Rasmussen K, Aghajanian GK. Potency of antipsychotics in re-versing the effects of a hallucinogenic drug on locus coeruleus neurons correlates with 5-HT2 binding affinity. Neuropsychopharmacology1988;1:101-107.
37.
Roth BL, Willins D, Kristiansen K, Kroeze W.Activation is hallucinogenic and antagonism is therapeutic: role of 5-HT receptors in atypical antipsychotic drug actions. Neuroscientist1999;5:254-262.
38.
Miller RJ, Hiley CR. Anti-muscarinic properties of neuroleptics and drug-induced parkinsonism. Nature (Lond)1974;248:546-547.
39.
Cohen BM, Lipinski JF. In vivo potencies of antipsychotic drugs in blocking alpha1 noradrenergic and dopamine D-2 receptors: implications for drug mechanisms of action. Life Sci1986;39:2571-2586.
40.
Hertel P, Fagerquuist M, Svensson T.Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by α2-adrenoceptor blockade. Science1999;286:105-107.
41.
Van Tol HHM, Bunzow JR, Guan HC, Sunahara H-C, Seeman P, Niznik HB, et al.Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Na-ture1991;350:610-614.
42.
Roth BL, Tandra S, Burgess LH, Sibley DR, Meltzer HY. D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology (Berl)1995;120:365-368.
43.
Roth BL, Ciaranello RD, Meltzer HY. Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors. J Pharmacol Exp Ther1992;260:1361-1365.
44.
Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, et al.Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 re-ceptors. J Pharmacol Exp Ther1994;268:1403-1410.
45.
Sorensen SM, Kehne JH, Fadayl EM, Humphreys TM, Ketteler HJ, Sullivan C, et al.Characterization of the 5-HT2 antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. J Pharmacol Exp Ther1993;266:684-691.
46.
Glennon RA, Titler M, McKenney JD. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci1984;35:2505-2511.
47.
Sanders-Bush E, Burris KD, Knoth K.Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are par-tial agonists at serotonin receptors linked to phosphoinositide hydrolysis. J Pharmacol Exp Ther1988;246:924-928.
48.
Grailhe R, Waeber C, Dulawa SC, Hornung JP, Zhuang X, Brunner D, et al.Increased exploratory activity and altered response to LSD in mice lacking the 5-HT(5A) receptor. Neuron1999;22:581-591.
49.
Kursar JD, Nelson DL, Wainscott DB, Baez M.Molecular cloning, functional expression, and mRNA tissue distribution of the human 5-hydroxytryptamine2B receptor. Mol Pharmacol1994;46:227-234.
50.
Cohen ML, Fludzinski LA. Contractile serotonergic receptor in rat stomach fundus. J Pharmacol Exp Ther1987;243:264-269.
51.
Choi DS, Colas JF, Kellermann O, Loric S, Launay JM, Rosay P, et al.The mouse 5-HT2B receptor: possible involvement in trophic functions of serotonin. Cell Mol Biol (Noisy-le-grand)1994;40:403-411.
52.
Ellis ES, Byrne C, Murphy OE, Tilford NS, Baxter GS. Mediation by 5-hydroxytryptamine2B receptors of endothelium-de-pendent relaxation in rat jugular vein. Br J Pharmacol1995;114:400-404.
53.
Pazos A, Hoyer D, Palacios JM. The binding of serotonergic ligands to the procine choroid plexus: characterization of a new type of serotonin recognition site. Eur J Pharmacol1984;106:539-546.
54.
Julius D, Huang KN, Livelli TJ, Axel R, Jessell TM. The 5HT2 receptor defines a family of structurally distinct but functionally conserved serotonin receptors. Proc Natl Acad Sci U S A1990;87:928-932.
55.
Choudhary MS, Craigo S, Roth BL. Identification of receptor domains that modify ligand binding to 5-hydroxytryptamine2 and 5-hydroxytryptamine1c serotonin receptors. Mol Pharmacol1992;42:627-633.
56.
Kennett GA, Wood MD, Glen A, Grewal S, Forbes I, Gadre A, et al.In vivo properties of SB 200646A, a 5-HT2C/2B receptor antagonist. Br J Pharmacol1994;111:797-802.
57.
Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, Dallman MF, Julius D.Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors [see comments]. Nature1995;374:542-546.
Nonogaki K, Strack AM, Dallman MF, Tecott LH. Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene [see comments]. Nat Med1998;4:1152-1156.
60.
Martin JR, Bos M, Jenck F, Moreau J, Mutel V, Sleight AJ, et al.5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. J Pharmacol Exp Ther1998;286:913-924.
61.
Bonhaus DW, Weinhardt KK, Taylor M, DeSouza A, McNeeley PM, Szczepanski K, et al.RS-102221: a novel high affinity and selective 5-HT2C receptor antagonist. Neuropharmacology1997;36:621-629.
62.
Kennett GA, Wood MD, Bright F, Trail B, Riley G, Holland V, et al.SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology1997;36:609-620.
63.
Halford JC, Lawton CL, Blundell JE. The 5-HT2 receptor agonist MK-212 reduces food intake and increases resting but pre-vents the behavioural satiety sequence. Pharmacol Biochem Behav1997;56:41-46.
64.
Samanin R, Garattini S.Pharmacology of ingestive behaviour. Therapie1996;51:107-115.
65.
Kennett GA, Pittaway K, Blackburn TP. Evidence that 5-HT2c receptor antagonists are anxiolytic in the rat Geller-Seifter model of anxiety. Psychopharmacology (Berl)1994;114:90-96.
66.
Kennett GA, Whitton P, Shah K, Curzon G.Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists. Eur J Pharmacol1989;164:445-454.
67.
Whitton P, Curzon G.Anxiogenic-like effect of infusing 1-(3-chlorophenyl) piperazine (mCPP) into the hippocampus. Psychopharmacology1990;100:138-140.
68.
Germine M, Goddard AW, Woods SW, Charney DS, Heninger GR. Anger and anxiety responses to m-chlorophenylpiperazine in generalized anxiety disorder. Biol Psychiatry1992;32:457-461.
69.
Krystal JH, Seibyl JP, Price LH, Woods SW, Heninger GR, Aghajanian GK, et al.m-Chlorophenylpiperazine (MCPP) ef-fects in neuroleptic-free schizophrenic patients. Arch Gen Psy-chiatry1993;50:624-635.
70.
Pigott TA, Hill JL, Grady TA, L’Heureux F, Bernstein S, Rubenstein CS, et al.A comparison of the behavioral effects of oral verses intravenous mCPP administration in OCD patients and the effect of metergoline prior to i.v. mCPP. Biol Psychiatry1993;33:3-14.
71.
Palvimaki EP, Roth BL, Majasuo H, Laakso A, Kuoppamaki M, Syvalahti E, et al.Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor. Psychopharmacology (Berl)1996;126:234-240.
72.
Burns CM, Chu H, Rueter SM, Hutchinson LK, Canton H, Sanders-Bush E, et al.Regulation of serotonin-2C receptor G-protein coupling by RNA editing. Nature1997;387:303-308.
73.
Liu Y, Emeson RB, Samuel CE. Serotonin-2C receptor pre-mRNA editing in rat brain and in vitro by splice site variants of the interferon-inducible double-stranded RNA-specific adenosine deaminase ADAR1. J Biol Chem1999;274:18351-18358.
74.
Rueter SM, Dawson TR, Emeson RB. Regulation of alternative splicing by RNA editing. Nature1999;399:75-80.
75.
Niswender CM, Sanders-Bush E, Emeson RB. Identification and characterization of RNA editing events within the 5-HT2C receptor. Ann N Y Acad Sci1998;861:38-48.
76.
Niswender CM, Copeland SC, Herrick-Davis K, Emeson RB, Sanders-Bush E.RNA editing of the human serotonin 5-hydroxytryptamine 2C receptor silences constitutive activity. J Biol Chem1999;274:9472-9478.
77.
Davies PA, Pistis M, Hanna MC, Peters JA, Lambert JJ, Hales TG, et al.The 5-HT3B subunit is a major determinant of seroto-nin-receptor function. Nature1999;397:359-363.
78.
Maricq AV, Peterson AS, Brake AJ, Myers RM, Julius D.Primary structure and functional expression of the 5HT3 receptor, a serotonin-gated ion channel. Science1991;254:432-437.
79.
Bloom FE, Morales M.The central 5-HT3 receptor in CNS disorders. Neurochem Res1998;23:653-659.
80.
Dumuis A, Sebben M, Bockaert J.BRL 24924: a potent agonist at a non-classical 5-HT receptor positively coupled with adenylate cyclase in colliculi neurons. Eur J Pharmacol1989;162:381-384.
81.
Buchheit KH, Gamse R, Pfannkuche HJ. SDZ 205-557, a selec-tive, surmountable antagonist for 5-HT4 receptors in the isolated guinea pig ileum. Naunyn Schmiedebergs Arch Pharmacol1992;345:387-393.
82.
Briejer MR, Akkermans LM, Meulemans AL, Lefebvre RA, Schuurkes JA. Cisapride and a structural analogue, R 76,186, are 5-hydroxytryptamine4 (5-HT4) receptor agonists on the guinea-pig colon ascendens. Naunyn Schmiedebergs Arch Pharmacol1993;347:464-470.
83.
Roth BL, Chuang DM. Multiple mechanisms of serotonergic signal transduction. Life Sci1987;41:1051-1064.
84.
Claeysen S, Sebben M, Becamel C, Bockaert J, Dumuis A.Novel brain-specific 5-HT4 receptor splice variants show marked constitutive activity: role of the C-terminal intracellular domain. Mol Pharmacol1999;55:910-920.
85.
Dumuis A, Sebben M, Bockaert J.The gastrointestinal prokinetic benzamide derivatives are agonists at the non-classical 5-HT receptor (5-HT4) positively coupled to adenylate cyclase in neurons. Naunyn Schmiedebergs Arch Pharmacol1989;340:403-410.
86.
Torres GE, Holt IL, Andrade R.Antagonists of 5-HT4 receptor-mediated responses in adult hippocampal neurons. J Pharmacol Exp Ther1994;271:255-261.
87.
Bockaert J, Claeysen S, Sebben M, Dumuis A.5-HT4 receptors: gene, transduction and effects on olfactory memory. Ann N Y Acad Sci1998;861:1-15.
88.
Matthes H, Boschert U, Amlaiky N, Grailhe R, Plassat J-L, Muscatelli F, et al.Mouse 5-hydroxytryptamine5A and 5-hydroxytryptamine5B receptors define a new family of serotonin receptors: cloning, functional expression and chromosomal localization. Mol Pharmacol1993;43:313-319.
89.
Francken BJ, Jurzak M, Vanhauwe JF, Luyten WH, Leysen JE. The human 5-ht5A receptor couples to Gi/Go proteins and inhibits adenylate cyclase in HEK 293 cells. Eur J Pharmacol1998;361:299-309.
90.
Waeber C, Grailhe R, Yu XJ, Hen R, Moskowitz MA. Putative 5-ht5 receptors: localization in the mouse CNS and lack of effect in the inhibition of dural protein extravisation. Ann N Y Acad Sci1998;861:85-90.
91.
Hoyer D, Martin GR. Classification and nomenclature of 5-HT receptors: a comment on current issues. Behav Brain Res1996;73:263-268.
92.
Saxena PR. Serotonin receptors: subtypes, functional responses and therapeutic relevance. Pharmacol Ther1995;66:339-368.
93.
Monsma FJ, Shen Y, Ward RP, Hamblin MW, Sibley DR. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol1993;43:320-327.
94.
Shen Y, Monsma FJ, Jr, Metcalf MA, Jose PA, Hamblin MW, Sibley DR. Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype. J Biol Chem1993;268:18200-18204.
95.
Lovenberg TW, Baron BM, de Lecea L, Miller JD, Prosser RA, Rea MA, et al.A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circa-dian rhythms. Neuron1993;11:449-458.
96.
Kohen R, Metcalf MA, Khan N, Druck T, Huebner K, Lachowicz JE, et al.Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor. J Neurochem1996;66:47-56.
97.
Bourson A, Boess FG, Bos M, Sleight AJ. Involvement of 5-HT6 receptors in nigro-striatal function in rodents. Br J Pharmacol1998;125:1562-1566.
98.
Boess FG, Riemer C, Bos M, Bentley J, Bourson A, Sleight AJ. The 5-hydroxytryptamine6 receptor-selective radioligand [3H]Ro 63-0563 labels 5-hydroxytryptamine receptor binding sites in rat and porcine striatum. Mol Pharmacol1998;54:577-583.
99.
Ward RP, Hamblin MW, Lachowicz JE, Hoffman BJ, Sibley DR, Dorsa DM. Localization of serotonin subtype 6 receptor messenger RNA in the rat brain by in situ hybridization histochemistry. Neuroscience1995;64:1105-1111.
100.
Gustafson EL, Durkin MM, Bard JA, Zgombick J, Branchek TA. A receptor autoradiographic and in situ hybridization analysis of the distribution of the 5-ht7 receptor in rat brain. Br J Pharmacol1996;117:657-666.
101.
Shimizu M, Nishida A, Zensho H, Yamawaki S.Chronic antide-pressant exposure enhances 5-hydroxytryptamine7 receptor-mediated cyclic adenosine monophosphate accumulation in rat frontocortical astrocytes. J Pharmacol Exp Ther1996;279:1551-1558.
102.
Selkirk JV, Scott C, Ho M, Burton MJ, Watson J, Gaster LM, et al.SB-224289—a novel selective (human) 5-HT1B receptor an-tagonist with negative intrinsic activity. Br J Pharmacol1998;125:202-208.
103.
Schlicker E, Fink K, Molderings GJ, Price GW, Duckworth M, Gaster L, et al.Effects of selective h5-HT1B (SB-216641) and h5-HT1D (BRL-15572) receptor ligands on guinea-pig and human 5-HT auto- and heteroreceptors. Naunyn Schmiedebergs Arch Pharmacol1997;356:321-327.
104.
Phebus LA, Johnson KW, Zgombick JM, Gilbert PJ, Van Belle K, Mancuso V, et al.Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine. Life Sci1997;61:2117-2126.
